Trisalus Life Sciences Inc Revenue Growth Rates (TLSI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Trisalus Life Sciences Inc   (NASDAQ: TLSI)
 

TLSI's Revenue Growth by Quarter and Year

Trisalus Life Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TLSI/growth
https://api.csimarket.com/api/v1/companies/TLSI/fundamentals
https://api.csimarket.com/api/v1/companies/TLSI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TLSI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.88
2nd Quarter June 11.41
1st Quarter March 8.67
FY 32.96





TLSI Revenue third quarter 2026 Y/Y Growth Comment
Trisalus Life Sciences Inc reported Revenue improvement of 20.81% year on year in the third quarter 2026, to $ 12.88 millions, this is lower than Trisalus Life Sciences Inc 's recent average Revenue rise of 48.1%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue growth. While Trisalus Life Sciences Inc ' s Revenue rise of 20.81% ranks overall at the positon no. 1799 in the third quarter 2026.


TLSI Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 20.81 %
2nd Quarter June 9.61 %
1st Quarter March 0 %
FY   -

Financial Statements
Trisalus Life Sciences Inc 's third quarter 2026 Revenue $ 12.88 millions TLSI's Income Statement
Trisalus Life Sciences Inc 's third quarter 2025 Revenue $ 10.66 millions Quarterly TLSI's Income Statement


TLSI Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.87 %
2nd Quarter June 31.6 %
1st Quarter March -39.96 %
FY (Year on Year)   -


Back to TLSI Growth rate Comparisons >> Back to TLSI Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #282
Overall #1799

Revenue Y/Y Growth Statistics
High Average Low
116.39 % 48.1 % -0.03 %
(Dec 31 2025)   (Mar 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #282
Overall #1799
Revenue Y/Y Growth Statistics
High Average Low
116.39 % 48.1 % -0.03 %
(Dec 31 2025)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Trisalus Life Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
54.56 % 9.71 % -39.98 %
(Jun 30 2023)  


TLSI's III. Quarter Q/Q Revenue Comment
Trisalus Life Sciences Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 12.87%, to $ 12.88 millions, from $11.41 millions in the second quarter.

Within Medical Equipment & Supplies industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Trisalus Life Sciences Inc 's Revenue growth quarter on quarter, overall rank is 355.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #19
Healthcare Sector #81
Overall #355
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #19
Healthcare Sector #81
Overall #355
Revenue Q/Q Growth Statistics
High Average Low
54.56 % 9.71 % -39.98 %
(Jun 30 2023)  


TLSI's III. Quarter Q/Q Revenue Comment
Trisalus Life Sciences Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 12.87%, to $ 12.88 millions, from $11.41 millions in the second quarter.

Within Medical Equipment & Supplies industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Trisalus Life Sciences Inc 's Revenue growth quarter on quarter, overall rank is 355.


Trisalus Life Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 47.40
Y / Y Revenue Growth (TTM) 25.04 %
Year on Year Revenue Growth Overall Ranking # 1625
Seqeuential Revenue Change (TTM) 4.91 %
Seq. Revenue Growth (TTM) Overall Ranking # 1745


Cumulative Revenue growth Comment
Assuming the Trisalus Life Sciences Inc 's fiscal year would have ended in Sep 30 2026, Trisalus Life Sciences Inc would have reprted above average annual Revenue rise of 25.04% year on year, of $ 47 millions.
This marks a slow-down of the companys growth trends and from the 30.61% improvement in Jun 30 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1125 to 1625.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 264
Overall # 1625

Revenue TTM Y/Y Growth Statistics
High Average Low
50.66 %
 22.58 %
8.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 279
S&P 500 # 1745
Cumulative Revenue growth Comment
Assuming the Trisalus Life Sciences Inc 's fiscal year would have ended in Sep 30 2026, Trisalus Life Sciences Inc would have reprted above average annual Revenue rise of 25.04% year on year, of $ 47 millions.
This marks a slow-down of the companys growth trends and from the 30.61% improvement in Jun 30 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1125 to 1625.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 264
Overall # 1625

Revenue TTM Y/Y Growth Statistics
High Average Low
50.66 %
22.58 %
8.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 279
S&P 500 # 1745




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TLSI's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions


About Trisalus Life Sciences Inc Revenue Growth Rates (TLSI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Trisalus Life Sciences Inc (CIK 1826667).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-072515
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Trisalus Life Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.